Byron Capital ups Cipher price target

Tweet Byron Capital Markets has raised its price target on “buy-rated” Cipher Pharmaceuticals (TSX:DND; OTCBB:CPHMF) to $6.25 from $5.25, after the company posted record results for the first quarter. The stock closed at $3.80 on Friday. “Our key takeaway is the Absorica launch is outperforming even our optimistic expectations,” writes analyst Doug Loe. On Absorica’s [...]

Cipher posts record first quarter results

Tweet First quarter net income for Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) was $1.5-million or 6 cents a share on revenue of $3.3-million, compared with a profit of $125,000 or 1 cent on revenue of $1.8-million a year ago. “We delivered record financial performance in the first quarter, reflecting the addition of new product revenue streams, especially [...]

Tecnofarma to distribute Cipher’s tramadol

Tweet Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) has entered into a definitive distribution and supply agreement with Tecnofarma International, giving Tecnofarma the exclusive right to market, sell and distribute CIP-Tramadol ER in Latin America. Uruguay-based Tecnofarma operates in 18 Latin American countries and will launch the product in certain territories, including Brazil and Mexico. CIP-Tramadol ER is [...]

Byron Capital starts Cipher at buy

Tweet Byron Capital Markets has upped Cipher Pharmaceuticals (TSX:DND; OTCBB:CPHMF) to a “buy” rating from an “idea of interest” last year with a price target of $4.50, after introducing formal EBITDA forecasts and a valuation for Cipher’s approved product portfolio. The stock closed at $2.70 on Friday. Analyst Doug Loe writes that Cipher’s “risk profile [...]

Cipher partner launches Absorica in U.S.

Tweet Cipher Pharmaceuticals (TSX:DND; OTCBB:CPHMF) announced that its partner, Ranbaxy Laboratories, has begun the sales and promotion of Absorica, Cipher’s novel, patented, brand formulation of the acne medication isotretinoin for the treatment of severe recalcitrant nodular acne. “The launch of Absorica, our third commercial product, represents a major milestone for Cipher and we look forward [...]

Health Canada clears Cipher acne medicine

Tweet Cipher Pharmaceuticals (TSX:DND) has received approval from Health Canada for its new drug submission for Epuris, a novel, brand formulation of the acne medication isotretinoin for the treatment of severe acne. Cipher expects to launch Epuris in Canada in the second quarter of 2013. The product is administered orally, once or twice daily, for [...]

Cipher posts strong third quarter results

Tweet Cipher Pharmaceuticals (TSX:DND; OTCBB:CPHMF) has reported third quarter net income of $800,000, compared with a year earlier loss of $200,000, as revenue rose 89% to $2.1-million. “Strong third-quarter revenues combined with consistent expense levels year-over-year allowed us to achieve substantially higher earnings and strengthened our cash balance,” CEO Larry Andrews said in the quarterly [...]

Cipher expands dermatology franchise

Tweet Cipher Pharmaceuticals (TSX:DND; OTCBB: CPHMF) has reached agreement with Institut Biochimique SA (IBSA), a closely held pharmaceutical company in Lugano, Switzerland, to obtain exclusive license and distribution rights in Canada to market the Betesil patch, a novel, patent-protected, self-adhesive medicated plaster, for the treatment of inflammatory skin conditions such as plaque psoriasis. “The Betesil [...]

Cipher NDA supported by MedAvante

Tweet MedAvante Central Ratings, used to assess the potential for psychiatric side effects in a non-psychiatric clinical program, was deemed an acceptable methodology for signal detection in Cipher Pharmaceuticals’ (TSX:DND; OTCBB: CPHMF) new drug application approved recently by the FDA. The FDA in May approved Cipher’s Absorica, a novel, patented brand formulation of the acne [...]

Zachs calls Cipher significantly undervalued

Tweet A discounted cash flow analysis by Zachs Investment Research values the shares of Cipher Pharmaceuticals (TSX:DND; OTCBB: CPHMF) at $3 a share. The stock is trading at $1.48 Wednesday afternoon. “Our model … shows that operating cash flow should turn positive in 2013 on a sustained basis,” writes analyst Jason Napodano, who rates Cipher [...]

Next Page »